|
Volumn 44, Issue 3, 2004, Pages 720-732
|
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
a a a a a a a a a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
HYPOCHOLESTEROLEMIC AGENT;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
AGED;
BLOOD;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
COMORBIDITY;
CONFERENCE PAPER;
CONSENSUS DEVELOPMENT;
CONTROLLED CLINICAL TRIAL;
DIABETES MELLITUS;
EVIDENCE BASED MEDICINE;
FIBRINOLYTIC THERAPY;
HEART INFARCTION;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPERTENSION;
MIDDLE AGED;
PATIENT EDUCATION;
PRACTICE GUIDELINE;
RANDOMIZED CONTROLLED TRIAL;
RISK;
RISK FACTOR;
STATISTICS;
AGED;
ANTICHOLESTEREMIC AGENTS;
ANTIHYPERTENSIVE AGENTS;
ANTILIPEMIC AGENTS;
CARDIOVASCULAR DISEASES;
CHOLESTEROL, LDL;
CLINICAL TRIALS;
COMORBIDITY;
DIABETES MELLITUS;
EVIDENCE-BASED MEDICINE;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPERCHOLESTEROLEMIA;
HYPERTENSION;
MIDDLE AGED;
MYOCARDIAL INFARCTION;
PATIENT EDUCATION;
PRACTICE GUIDELINES;
RANDOMIZED CONTROLLED TRIALS;
RISK;
RISK FACTORS;
THROMBOLYTIC THERAPY;
|
EID: 4544275379
PISSN: 07351097
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jacc.2004.07.001 Document Type: Conference Paper |
Times cited : (1201)
|
References (45)
|